Definitely more questions than answers with this and would not be surprised to feel the same way after the incoming webinar.
I can see the bigger picture with the facility acquired and the licence of this drug but as many have stated the cap raise is questionable and I 'm sure be glossed over during any interview.
I am well invested here and taken the risk with this company and will own the outcome.
Let's see how this all pans out over the next 6-12months
Seems the games are really starting to be played on all fronts, backing the team though!
Ann: Imugene Licenses Allogeneic CD19 CAR T Cell Therapy, page-359
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.4¢ |
Change
-0.001(1.82%) |
Mkt cap ! $396.8M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.6¢ | 5.4¢ | $443.4K | 8.072M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 27 | 3056419 | 5.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.5¢ | 120000 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |